An experimental drug for multiple sclerosis (MS) that was approved in 2004, then abruptly yanked off shelves last year because of safety concerns, may get a second chance.
Two studies show that the drug can curb MS symptoms and slow progression of the autoimmune disease over 2 years, the longest tests of this drug to date.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.